Search

Your search keyword '"Jingyan Pei"' showing total 4 results
Start Over Author "Jingyan Pei"
Sorry, I don't understand your search. ×
4 results on '"Jingyan Pei"'

1. Advances in the stability challenges of bioactive peptides and improvement strategies

Author

Jingyan Pei, Xinchang Gao, Daodong Pan, Ying Hua, Jun He, Zhu Liu, and Yali Dang

Subjects
Bioactive peptide, Quality stability, Property stability, Digestion stability, Metabolism stability, Improvement strategy, Nutrition. Foods and food supply, TX341-641, Food processing and manufacture, TP368-456
Abstract

Bioactive peptides are widely used in functional foods due to their remarkable efficacy, selectivity, and low toxicity. However, commercially produced bioactive peptides lack quality stability between batches. Furthermore, the efficacies of bioactive peptides cannot be guaranteed in vivo due to gastrointestinal digestion and rapid plasma, liver, and kidney metabolism. The problem of poor stability has restricted the development of peptides. Bioactive peptide stability assessments use different stability assays, so the results of different studies are not always comparable. This review summarizes the quality stability challenges in the enzymatic hydrolysis production of bioactive peptides and the metabolism stability challenges after oral administration. Future directions on the strategies for improving their stability are provided. It was proposed that we use fingerprinting as a quality control measure using qualitative and quantitative characteristic functional peptide sequences. The chemical modification and encapsulation of bioactive peptides in microcapsules and liposomes are widely used to improve the digestive and metabolic stability of bioactive peptides. Additionally, the establishment of a universal stability test and a unified index would greatly improve uniformity and comparability in research into bioactive peptides. In summary, the reliable evaluation of stability is an essential component of peptide characterization, and these ideas may facilitate further development and utilization of bioactive peptides.

Published
2022
Full Text
View/download PDF

2. Transport, Stability, and In Vivo Hypoglycemic Effect of a Broccoli-Derived DPP-IV Inhibitory Peptide VPLVM

Author

Jingyan Pei, Zhu Liu, Daodong Pan, Yufen Zhao, Yali Dang, and Xinchang Gao

Subjects
Dipeptidyl-Peptidase IV Inhibitors, Dipeptidyl Peptidase 4, Diabetes Mellitus, Humans, Hypoglycemic Agents, General Chemistry, Brassica, Caco-2 Cells, General Agricultural and Biological Sciences, Peptides
Abstract

Diabetes is a major metabolic disease that requires long-term pharmacotherapy. Bioactive peptides have unique advantages such as higher potency, selectivity, and safety over small molecules and have achieved great success in the treatment of diabetes. We previously isolated a dipeptidyl peptidase-IV (DPP-IV) inhibitory peptide VPLVM with IC

Published
2022

3. Novel Broccoli-Derived Peptides Hydrolyzed by Trypsin with Dual-Angiotensin I-Converting Enzymes and Dipeptidyl Peptidase-IV-Inhibitory Activities

Author

Jingyan Pei, Daodong Pan, Zhu Liu, Tingyi Zhou, Yali Dang, Xinchang Gao, and Yufen Zhao

Subjects
chemistry.chemical_classification, Dipeptidyl-Peptidase IV Inhibitors, Chemistry, Angiotensin-Converting Enzyme Inhibitors, General Chemistry, Brassica, Pharmacology, medicine.disease, Trypsin, Hydrolysate, Dipeptidyl peptidase, Rats, Mice, Enzyme, Oral administration, Diabetes mellitus, Renin–angiotensin system, medicine, Animals, Angiotensin I, General Agricultural and Biological Sciences, Peptides, IC50, medicine.drug
Abstract

Broccoli-derived peptides show beneficial metabolic effects, and it is necessary to examine their exact functional sequences. First, peptides from the trypsin hydrolysate of broccoli proteins were isolated and identified using column chromatography and quadrupole time-of-flight mass spectrometry. After that, their functions were verified by oral administration. The results identified two novel peptides as Leu-Pro-Gly-Val-Leu-Pro-Val-Ala (LPGVLPVA) and Tyr-Leu-Tyr-Ser-Pro-Ala-Tyr (YLYSPAY). LPGVLPVA exhibited an ACE IC50 value of 0.776 ± 0.03 μM and a DPP-IV IC50 value of 392 ± 24 μM; YLYSPAY showed an ACE IC50 value of 8.52 ± 0.63 μM and a DPP-IV IC50 value of 181 ± 4 μM. Administration of the peptides reduced the blood pressure of spontaneously hypertensive rats and reduced blood glucose levels in the oral glucose tolerance test in mice. The results indicated that LPGVLPVA and YLYSPAY could be potential nutritional candidates for hypertensive and diabetic people, especially for those with diabetes associated with hypertension.

Published
2021

4. Transport, In Vivo Antihypertensive Effect, and Pharmacokinetics of an Angiotensin-Converting Enzyme (ACE) Inhibitory Peptide LVLPGE

Author

Jingyan Pei, Xinchang Gao, Yali Dang, Ying Hua, Tingyi Zhou, and Yongdong Wang

Subjects
0106 biological sciences, Angiotensins, Cmax, Peptide, Angiotensin-Converting Enzyme Inhibitors, Blood Pressure, Pharmacology, 01 natural sciences, Pharmacokinetics, In vivo, Oral administration, Rats, Inbred SHR, Animals, Humans, Antihypertensive Agents, chemistry.chemical_classification, biology, 010401 analytical chemistry, Transporter, Angiotensin-converting enzyme, General Chemistry, 0104 chemical sciences, Rats, Enzyme, chemistry, Hypertension, biology.protein, Caco-2 Cells, General Agricultural and Biological Sciences, Peptides, 010606 plant biology & botany
Abstract

The angiotensin-converting enzyme (ACE) inhibitory peptide LVLPGE provides outstanding antihypertensive effects in vivo, with a maximum systolic blood pressure (SBP) drop of 39 mmHg at a dose of 10 mg/kg. We evaluated the gastrointestinal digestion, transport, and in vivo antihypertensive effects of LVLPGE at different doses. LVLPGE was resistant to gastrointestinal enzymes with a stability of 97.8% and a permeability Papp of (5.09 ± 0.94) × 10-7 cm/s. LVLPGE was mainly transported through the Caco-2 cell monolayer by the peptide transporter PepT 1 and passive-mediated transport. LVLPGE at doses of 30 and 50 mg/kg had a positive antihypertensive effect in vivo; 30 mg/kg had a more significant effect than 50 mg/kg. After oral administration, the pharmacokinetics of LVLPGE showed that the Cmax was 4.65 ng/mL at 2 min. The blood pressure-lowering effect increased as the concentration of LVLPGE increased in the plasma of spontaneous hypertensive rats (SHRs).

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results